A palliative Quad Shot radiotherapy regimen alongside concurrent immunotherapy can improve local control in symptomatic patients with head and neck cancer but may not improve overall survival.
Physicians should feel reassured in recommending active surveillance as a management strategy for low-risk cancers, as no successful malpractice cases related to this approach have been found.